Cargando…

Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy

Amplifying “eat me signal” during tumor immunogenic cell death (ICD) cascade is crucial for tumor immunotherapy. Inspired by the indispensable role of adenosine triphosphate (ATP, a necessary “eat me signal” for ICD), a versatile ICD amplifier was developed for chemotherapy-sensitized immunotherapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jiulong, Sun, Xiaoyan, Zhao, Xiufeng, Yang, Chunrong, Shi, Menghao, Zhang, Benzhuo, Hu, Haiyang, Qiao, Mingxi, Chen, Dawei, Zhao, Xiuli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513492/
https://www.ncbi.nlm.nih.gov/pubmed/36176905
http://dx.doi.org/10.1016/j.apsb.2022.05.008
_version_ 1784798076759703552
author Zhang, Jiulong
Sun, Xiaoyan
Zhao, Xiufeng
Yang, Chunrong
Shi, Menghao
Zhang, Benzhuo
Hu, Haiyang
Qiao, Mingxi
Chen, Dawei
Zhao, Xiuli
author_facet Zhang, Jiulong
Sun, Xiaoyan
Zhao, Xiufeng
Yang, Chunrong
Shi, Menghao
Zhang, Benzhuo
Hu, Haiyang
Qiao, Mingxi
Chen, Dawei
Zhao, Xiuli
author_sort Zhang, Jiulong
collection PubMed
description Amplifying “eat me signal” during tumor immunogenic cell death (ICD) cascade is crucial for tumor immunotherapy. Inspired by the indispensable role of adenosine triphosphate (ATP, a necessary “eat me signal” for ICD), a versatile ICD amplifier was developed for chemotherapy-sensitized immunotherapy. Doxorubicin (DOX), ATP and ferrous ions (Fe(2+)) were co-assembled into nanosized amplifier (ADO-Fe) through π‒π stacking and coordination effect. Meanwhile, phenylboric acid-polyethylene glycol-phenylboric acid (PBA-PEG-PBA) was modified on the surface of ADO-Fe (denoted as PADO-Fe) by the virtue of d-ribose unit of ATP. PADO-Fe could display active targetability against tumor cells via sialic acid/PBA interaction. In acidic microenvironment, PBA-PEG-PBA would dissociate from amplifier. Moreover, high H(2)O(2) concentration would induce hydroxyl radical (·OH) and oxygen (O(2)) generation through Fenton reaction by Fe(2+). DOX and ATP would be released from the amplifier, which could induce ICD effect and “ICD adjuvant” to amplify this process. Together with programmed death ligands 1 (PD-L1) checkpoint blockade immunotherapy, PADO-Fe could not only activate immune response against primary tumor, but also strong abscopal effect against distant tumor. Our simple and multifunctional ICD amplifier opens a new window for enhancing ICD effect and immune checkpoint blockade therapy.
format Online
Article
Text
id pubmed-9513492
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-95134922022-09-28 Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy Zhang, Jiulong Sun, Xiaoyan Zhao, Xiufeng Yang, Chunrong Shi, Menghao Zhang, Benzhuo Hu, Haiyang Qiao, Mingxi Chen, Dawei Zhao, Xiuli Acta Pharm Sin B Original Article Amplifying “eat me signal” during tumor immunogenic cell death (ICD) cascade is crucial for tumor immunotherapy. Inspired by the indispensable role of adenosine triphosphate (ATP, a necessary “eat me signal” for ICD), a versatile ICD amplifier was developed for chemotherapy-sensitized immunotherapy. Doxorubicin (DOX), ATP and ferrous ions (Fe(2+)) were co-assembled into nanosized amplifier (ADO-Fe) through π‒π stacking and coordination effect. Meanwhile, phenylboric acid-polyethylene glycol-phenylboric acid (PBA-PEG-PBA) was modified on the surface of ADO-Fe (denoted as PADO-Fe) by the virtue of d-ribose unit of ATP. PADO-Fe could display active targetability against tumor cells via sialic acid/PBA interaction. In acidic microenvironment, PBA-PEG-PBA would dissociate from amplifier. Moreover, high H(2)O(2) concentration would induce hydroxyl radical (·OH) and oxygen (O(2)) generation through Fenton reaction by Fe(2+). DOX and ATP would be released from the amplifier, which could induce ICD effect and “ICD adjuvant” to amplify this process. Together with programmed death ligands 1 (PD-L1) checkpoint blockade immunotherapy, PADO-Fe could not only activate immune response against primary tumor, but also strong abscopal effect against distant tumor. Our simple and multifunctional ICD amplifier opens a new window for enhancing ICD effect and immune checkpoint blockade therapy. Elsevier 2022-09 2022-05-16 /pmc/articles/PMC9513492/ /pubmed/36176905 http://dx.doi.org/10.1016/j.apsb.2022.05.008 Text en © 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Zhang, Jiulong
Sun, Xiaoyan
Zhao, Xiufeng
Yang, Chunrong
Shi, Menghao
Zhang, Benzhuo
Hu, Haiyang
Qiao, Mingxi
Chen, Dawei
Zhao, Xiuli
Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy
title Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy
title_full Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy
title_fullStr Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy
title_full_unstemmed Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy
title_short Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy
title_sort combining immune checkpoint blockade with atp-based immunogenic cell death amplifier for cancer chemo-immunotherapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513492/
https://www.ncbi.nlm.nih.gov/pubmed/36176905
http://dx.doi.org/10.1016/j.apsb.2022.05.008
work_keys_str_mv AT zhangjiulong combiningimmunecheckpointblockadewithatpbasedimmunogeniccelldeathamplifierforcancerchemoimmunotherapy
AT sunxiaoyan combiningimmunecheckpointblockadewithatpbasedimmunogeniccelldeathamplifierforcancerchemoimmunotherapy
AT zhaoxiufeng combiningimmunecheckpointblockadewithatpbasedimmunogeniccelldeathamplifierforcancerchemoimmunotherapy
AT yangchunrong combiningimmunecheckpointblockadewithatpbasedimmunogeniccelldeathamplifierforcancerchemoimmunotherapy
AT shimenghao combiningimmunecheckpointblockadewithatpbasedimmunogeniccelldeathamplifierforcancerchemoimmunotherapy
AT zhangbenzhuo combiningimmunecheckpointblockadewithatpbasedimmunogeniccelldeathamplifierforcancerchemoimmunotherapy
AT huhaiyang combiningimmunecheckpointblockadewithatpbasedimmunogeniccelldeathamplifierforcancerchemoimmunotherapy
AT qiaomingxi combiningimmunecheckpointblockadewithatpbasedimmunogeniccelldeathamplifierforcancerchemoimmunotherapy
AT chendawei combiningimmunecheckpointblockadewithatpbasedimmunogeniccelldeathamplifierforcancerchemoimmunotherapy
AT zhaoxiuli combiningimmunecheckpointblockadewithatpbasedimmunogeniccelldeathamplifierforcancerchemoimmunotherapy